» Articles » PMID: 17382544

Tetrahydroindazole Inhibitors of Bacterial Type II Topoisomerases. Part 2: SAR Development and Potency Against Multidrug-resistant Strains

Abstract

We have previously reported a novel class of tetrahydroindazoles that display potency against a variety of Gram-positive and Gram-negative bacteria, potentially via interaction with type II bacterial topoisomerases. Herein are reported SAR investigations of this new series. Several compounds possessing broad-spectrum potency were prepared. Further, these compounds exhibit activity against multidrug-resistant Gram-positive microorganisms equivalent to that against susceptible strains.

Citing Articles

Molecular mechanism of a triazole-containing inhibitor of DNA gyrase.

Gedeon A, Yab E, Dinut A, Sadowski E, Capton E, Dreneau A iScience. 2024; 27(10):110967.

PMID: 39429773 PMC: 11489056. DOI: 10.1016/j.isci.2024.110967.


BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections.

Hameed P S, Kotakonda H, Sharma S, Nandishaiah R, Katagihallimath N, Rao R Nat Commun. 2024; 15(1):8202.

PMID: 39294149 PMC: 11410943. DOI: 10.1038/s41467-024-52557-2.


Dynamic Profiling and Binding Affinity Prediction of NBTI Antibacterials against DNA Gyrase Enzyme by Multidimensional Machine Learning and Molecular Dynamics Simulations.

Kokot M, Minovski N ACS Omega. 2024; 9(16):18278-18295.

PMID: 38680300 PMC: 11044241. DOI: 10.1021/acsomega.4c00036.


Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance.

Collins J, Osheroff N ACS Infect Dis. 2024; 10(4):1097-1115.

PMID: 38564341 PMC: 11019561. DOI: 10.1021/acsinfecdis.4c00128.


Exploring Alternative Pathways to Target Bacterial Type II Topoisomerases Using NBTI Antibacterials: Beyond Halogen-Bonding Interactions.

Kokot M, Novak D, Zdovc I, Anderluh M, Hrast M, Minovski N Antibiotics (Basel). 2023; 12(5).

PMID: 37237833 PMC: 10215804. DOI: 10.3390/antibiotics12050930.